Stay updated on Pralsetinib in RET+ Cancer Clinical Trial

Sign up to get notified when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pralsetinib in RET+ Cancer Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    A note that publications are automatically filled from PubMed was added, and the revision label updated from v3.2.0 to v3.3.2.
    Difference
    0.1%
    Check dated 2025-11-26T08:31:45.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The page no longer displays a government funding status notice. Core trial details, enrollment status, eligibility criteria, and location information remain unchanged.
    Difference
    0.2%
    Check dated 2025-11-19T09:17:56.000Z thumbnail image
  4. Check
    40 days ago
    Change Detected
    Summary
    No significant changes detected between the old and new screenshots; the page content and layout appear unchanged.
    Difference
    0.2%
    Check dated 2025-10-28T13:22:13.000Z thumbnail image
  5. Check
    62 days ago
    Change Detected
    Summary
    Page now reflects a new release (v3.2.0) and an urgent operating-status notice due to funding gaps; an older resource topic (Medullary thyroid carcinoma) is removed.
    Difference
    1%
    Check dated 2025-10-06T04:22:19.000Z thumbnail image
  6. Check
    69 days ago
    Change Detected
    Summary
    Core term updated: 'Medullary thyroid gland carcinoma' → 'Medullary thyroid carcinoma'; page version updated from v3.0.2 to v3.1.0.
    Difference
    0.0%
    Check dated 2025-09-28T23:40:23.000Z thumbnail image
  7. Check
    83 days ago
    Change Detected
    Summary
    Page revision updated from v3.0.1 to v3.0.2; the 'Back to Top' link was removed.
    Difference
    0.1%
    Check dated 2025-09-14T18:45:27.000Z thumbnail image

Stay in the know with updates to Pralsetinib in RET+ Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.